Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease

NCT00557921 is registered in ClinicalTrials.gov with Cogentus Pharmaceuticals as lead sponsor.

NCT NCT00557921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00557921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared With Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease
Lead sponsor
Cogentus Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
December 31, 2007
Completion date
November 30, 2009
Enrollment
5,000 (estimated)
Sites
491

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, coronary artery disease, myocardial infarction, percutaneous coronary intervention